FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression. Preclinical evidence suggests that baseline elevated tumor glucose metabolism as quantified by FDG-PET ([(18)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, James L, Appelbaum, Daniel E, Kocherginsky, Masha, Cowey, Charles L, Kimryn Rathmell, Wendy, McDermott, David F, Stadler, Walter M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799289/
https://www.ncbi.nlm.nih.gov/pubmed/24156027
http://dx.doi.org/10.1002/cam4.102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799289/
https://www.ncbi.nlm.nih.gov/pubmed/24156027
http://dx.doi.org/10.1002/cam4.102

Ejemplares similares